Integra LifeSciences (NASDAQ:IART) Issues Q3 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its third quarter 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.550-0.590 for the period, compared to the consensus EPS estimate of 0.560. The company issued revenue guidance of $410.0 million-$412.0 million. Integra LifeSciences also updated its FY 2026 guidance to 2.300-2.400 EPS.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on IART shares. UBS Group began coverage on Integra LifeSciences in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price target for the company. BMO Capital Markets started coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price objective on the stock. Wall Street Zen downgraded Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Thursday, June 18th. Finally, Truist Financial raised shares of Integra LifeSciences to a “hold” rating in a report on Thursday. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $18.86.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $16.09 on Friday. The company has a market capitalization of $1.25 billion, a PE ratio of -178.76, a PEG ratio of 0.84 and a beta of 1.21. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $20.49. The stock’s 50 day moving average price is $16.83 and its 200-day moving average price is $15.17.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities analysts anticipate that Integra LifeSciences will post 2.46 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.